Apotex Inc, a Canada-based global health company, announced on Friday that Health Canada has approved Apo-Semaglutide InjectionTM, a generic equivalent of Ozempic (semaglutide injection).

Apotex is the first Canada-based pharmaceutical company to gain authorisation for a generic equivalent of Ozempic. Semaglutide Injection will be the first Canadian generic equivalent to offer both the 2 mg/pen (0.68mg/mL) and 4 mg/pen (1.34 mg/mL) pen formats commercially, aligning with all brand equivalent SKUs.

Developed in partnership with Orbicular Pharmaceutical Technologies, Semaglutide Injection has undergone Health Canada's standard regulatory review for peptide medicines.

In Canada, semaglutide injection is indicated for the once-weekly treatment of adults with type 2 diabetes mellitus to improve glycaemic control, in combination with diet and exercise.